INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Tax withholdingVerified data

DeLucia David reported FGEN

Chief Financial Officer · KYNTRA BIO, INC. · FIBROGEN INC

Side
F
Value
$438
Shares
52
Price
$8.42
Executed
Dec 6, 2025
Disclosed
Dec 9, 2025
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Dec 6 executedDec 9, 2025 disclosed

FGEN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+1 / 25

$438 reported value · 1.2% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · FGEN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    15
    DD
    DeLucia DavidChief Financial Officer
    KYNBKYNTRA BIO, INC.
    Tax withholding
    		F$188
    22 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    11
    WT
    Wettig ThaneDirector, CEO
    KYNBKYNTRA BIO, INC.
    Tax withholding
    		F$1,787
    209 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    9
    DD
    DeLucia DavidChief Financial Officer
    KYNBKYNTRA BIO, INC.
    Tax withholding
    		F$349
    52 sh
    		Jun 6, 2026Jun 9, 2026
    traded Jun 6, 2026
    		+3dSEC FORM 4

    Evidence

    5
    WT
    Wettig ThaneDirector, CEO
    KYNBKYNTRA BIO, INC.
    Tax withholding
    		F$1,329
    198 sh
    		Jun 6, 2026Jun 9, 2026
    traded Jun 6, 2026
    		+3dSEC FORM 4

    Evidence

    9
    DD
    DeLucia DavidChief Financial Officer
    KYNBKYNTRA BIO, INC.
    Tax withholding
    		F$410
    60 sh
    		Mar 6, 2026Mar 10, 2026
    traded Mar 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    DD
    DeLucia DavidChief Financial Officer
    KYNBKYNTRA BIO, INC.
    Grant or award
    		A—
    26.0K sh
    		Feb 3, 2026Feb 5, 2026
    traded Feb 3, 2026
    		+2dSEC FORM 4

    Evidence

    5
    WT
    Wettig ThaneDirector, CEO
    KYNBKYNTRA BIO, INC.
    Grant or award
    		A—
    60.0K sh
    		Feb 3, 2026Feb 5, 2026
    traded Feb 3, 2026
    		+2dSEC FORM 4

    Evidence

    5
    WT
    Wettig ThaneDirector, CEO
    FGENKYNTRA BIO, INC.
    Tax withholding
    		F$2,181
    259 sh
    		Dec 6, 2025Dec 9, 2025
    traded Dec 6, 2025
    		+3dSEC FORM 4

    Evidence

    29
    WT
    Wettig ThaneDirector, CEO
    FGENKYNTRA BIO, INC.
    Open-market purchase
    		BUY$25K
    2,700 sh
    		Nov 17, 2025Nov 17, 2025
    traded Nov 17, 2025
    		+0dSEC FORM 4

    Evidence

    29
    WT
    Wettig ThaneDirector, CEO
    FGENKYNTRA BIO, INC.
    Open-market purchase
    		BUY$9,180
    1,000 sh
    		Nov 13, 2025Nov 17, 2025
    traded Nov 13, 2025
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002040705-25-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 6, 2025
    Published
    Dec 9, 2025
    Ingested by INSIDER
    Nov 5, 04:28 UTC
    Last re-read
    Nov 5, 04:28 UTC

    Extracted facts

    Filer
    DeLucia David
    Role
    Chief Financial Officer
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    FIBROGEN INC
    Ticker
    FGEN
    Shares
    52
    Price per share
    $8.42
    Value
    $438
    Execution date (reported)
    Dec 6, 2025
    Owned after transaction
    4,489 shares
    Days from execution to publication
    3

    Calculation

    Value = shares × reported price per share

    • Shares: 52
    • Price: $8.42

    = $438

    What this establishes

    DeLucia David filed this Form 4 reporting a tax withholding of FGEN on Dec 6, 2025. It became public on Dec 9, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    DeLucia Davidcik:0002040705
    Issuer
    KYNTRA BIO, INC.cik:0000921299

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for FGEN is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.